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Editorial
Genetic change in the cancer cell
The association of the chromosomal location of cellular proto-oncogenes with the
exchange points involved in specific chromosomal rearrangements observed in
particular human neoplasms has drawn attention once again to the role of alterations in
the cellular genome in the initiation and maintenance of neoplasia. The recent
observations have not only shed new light on old problems, they have also led to a
more critical appraisal of the available data with some intriguing results. It seems likely
that even a detailed understanding of these associations may not fully explain the loss
of growth control and the aberrant cell behaviour observed in cancer.
There are now several examples of the close association of specific chromosomal
exchange points in human neoplasms with the location of cellular proto-oncogenes
(summarized by Rowley, 1983). The classic translocation between chromosomes 9 and
22 in chronic granulocytic leukaemia (CGL) involves a breakpoint on chromosome 9
close to the c-abl gene which is translocated to the abnormal chromosome 22 (the
Philadelphia chromosome) (de Klein et al., 1982). There is now some evidence of
abnormal expression of the translocated c-abl gene in a CGL derived cell line (Collins
& Groudine, 1983). It is hard to avoid the conclusion, because of the specificity of the
rearrangement, that the c-abl oncogene is in some way involved in the abnormal
proliferation of the myeloid cells in CGL. More direct evidence of involvement of a
cellular proto-oncogene comes from the case of the t(8; 14) translocation in B cell
lymphomas (Dalla-Favera et al., 1982). In that case it is clear that the c-myc gene and
the immunoglobulin (Ig) genes are directly invloved in the exchanges (Taub et al., 1982;
Adams et al., 1983). The argument for a causal relationship is strengthened by the
closely analogous mouse model where junction fragments between a proto-oncogene
and the Ig genes have been recognized, e.g. the translocation between c-myc and the Ca
region of IgA and IgG producing mouse myeloma lines (Dean et al., 1983) or between
c-myc and both Cy2b and VH genes in another myeloma line (Neuberger & Calabi, 1983).
If these arrangements are a vital part of oncogenesis why is it that they appear to
occur in only a minority of neoplasms and then not in all cases nor in all cells? Part of
the answer is certainly that we have not looked in the right way nor thoroughly enough.
Recent reports suggest that specific translocations involving chromosome 8 along with
chromosomes 14, 2 or 22 do occur in all Burkitt tumours if adequately studied (Berger
& Bernheim, 1982; Bernheim et al., 1983). Similarly, the paradox of the specific t(15; 17)
translocations occurring in only some cells of some cases of acute promyelocytic
leukaemia seems to have been explained by the observation by Berger et al. (1983) that
slight differences in technique may favour the recognition of chromosomally normal
erythroblasts at the expense of the translocation carrying leukaemic promyelocytes. New
specific aberrations are being discovered regularly such as the t(6;9) translocation which
appears to define a specific sub-group of acute myeloid leukaemias (Vermaelen et al.,
1983; Schwartz et al., 1983; Sandberg et al., 1983).
Other classes of genomic change not overtly connected with chromosomal change are
being recognized. The single base change at position 35, in the c-ras' gene recovered by
transfection of DNA from the T24 human bladder carcinoma line into NIH 3T3 cells
provides the first direct evidence of the involvement of point mutation in human2 EDITORIAL
neoplasia (Reddy et al., 1982; Tabin et al., 1982; Taparowsky et al., 1982). The
guanosine to thymidine mutation which changes amino acid 12 from glycine to valine
confers on the gene product transforming properties not possessed by the unaltered gene
product. It appears that this change is a dominant expression of the altered gene
product, but without suitable gene markers in the original cell and since DNA mediated
transformation is only possible in already abnormal cell lines such as NIH 3T3 we
cannot be absolutely sure of this.
Deletion or chromosome loss also seem possible routes to the expression of the
malignant phenotype. Specific chromosomal deletions have been associated for some
time with a proportion of cases of Wilms' tumour and of retinoblastoma. More specific
evidence comes from the recent observation by Cavenee et al. (1983) that in
retinoblastoma patients heterozygous for variants of esterase D (an enzyme closely
linked to the retinoblastoma locus) and for restriction site polymorphisms on
chromosome 13, the cells of the tumour express only one allele, strongly suggesting a
deletion in, or complete loss of one chromosome 13 and it is tempting to speculate that
this hemizygosity permits expression of a gene on the homologous chromosome in some
way associated with the malignant behaviour. The danger of jumping to conclusions is,
however, demonstrated by the recent observation that the c-rasH gene lies outside the
segment of chromosome 11 deleted in Wilms' aniridia patients (Huerre et al., 1983; de
Martinville & Francke, 1983).
There is thus mounting evidence that these very specific genomic changes are part of
the neoplastic process. However, there is also evidence to suggest that while they may
be essential they may not be sufficient to lead to frank neoplasia. For example,
translocation of the c-abl and c-cis genes in t(9; 22) exchange is not sufficient to give
loss of cellular control in the erythroid cell lineage in CGL patients. Similarly in ataxia
telangiectasia specific translocations involving 14q12 are associated with clonal
proliferation of lymphocytes without overall loss of control on white cell numbers
(Taylor, 1982). Something more catastrophic must occur before uncontrolled neoplasia
arises.
Most advanced tumours have grossly abnormal chromosomes with loss, gain and
rearrangement. Second, gene amplification (which appears vital in developing drug
resistance in some cancers) is exceptionally difficult to induce in normal cells but easy to
induce in undifferentiated tumour cells; tumour cells showing some degree of
differentiation can be induced to undergo gene amplification only with difficulty (Fox,
1983). This could suggest that the more advanced malignant phenotype is accompanied
by a very significant loosening of the controls on the precision of DNA replication and
of chromosomal segregation. It seems possible that early and highly specific changes be
they exchange, point mutation or deletion may lead directly or indirectly to a
breakdown in the precise controls and that this may in turn lead on to neoplasia.
We have now become familiar with the concept of the fluidity of the genotype of the
somatic cell in both a functional and evolutionary sense. In the former case the
generation of antibody diversity involves major genomic rearrangements while antigenic
changes in some lower organisms are determined by the movement of genes or groups
of genes into expression loci. In an evolutionary sense we have evidence of gene
amplification followed by modification as well as the derivation of pseudogenes via
RNA intermediates. It is pleasing therefore that the role of Barbara McClintock in
having the audacity to challenge the idea of the static genome over forty years ago
should now be acknowledged by the award of a Nobel Prize (an appreciation by J.EDITORIAL 3
Maddox, 1983). Knowledge of how the mobility of the genome is controlled and how it
may be lost may well be critical in understanding neoplasia.
The Paterson Laboratories
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